| Literature DB >> 28421431 |
A Yu Roman1,2, E A Kovrazhkina3, O D Razinskaya3, M S Kukharsky1, A V Maltsev4, R K Ovchinnikov1, O A Lytkina1, A P Smirnov3, A A Moskovtsev5, Yu V Borodina6, A P Surguchov7, A A Ustyugov1, N N Ninkina1,5, V I Skvortsova3.
Abstract
In this study, we analyzed serum for the presence of antibodies to gamma-synuclein in patients with amyotrophic lateral sclerosis (ALS) compared to the control group of patients with other neurological diseases and healthy control donors. As a result, antibodies against gamma-synuclein are not an ALS-specific feature and have been identified in patients with ALS as well as in the control group patients. Patients with the impaired cerebral circulation showed increased incidence of autoantibodies to gamma-synuclein, yet the difference lacks statistical representativeness due to limited sample size.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28421431 DOI： 10.1134/S1607672917010197
Source DB: PubMed Journal: Dokl Biochem Biophys ISSN： 1607-6729 Impact factor: 0.788